Stockscreener 앱 받기
1.36
0.73%
-0.01
전일 마감가:
$1.37
열려 있는:
$1.36
하루 거래량:
18,921
Relative Volume:
0.02
시가총액:
$6.43M
수익:
-
순이익/손실:
$-6.78M
주가수익비율:
-0.0319
EPS:
-42.6996
순현금흐름:
$-4.67M
1주 성능:
-8.72%
1개월 성능:
-2.86%
6개월 성능:
-19.53%
1년 성능:
-5.62%
1일 변동 폭
$1.35
$1.39
1주일 범위
$1.35
$1.51
52주 변동 폭
$0.9512
$2.30
Clearmind Medicine Inc Stock (CMND) Company Profile
CMND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.36 | 6.43M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.94 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.11 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
662.88 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.25 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.00 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds - MSN
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing - Marketscreener.com
Clearmind Medicine (NASDAQ:CMND) Trading Up 6.3% – Still a Buy? - Defense World
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Clearmind Medicine Announces Shareholders Meeting Results - The Manila Times
Scisparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - Marketscreener.com
SciSparc and Clearmind Medicine Advance with European Patent Application for Psychedelic Binge Behavior Treatment - TipRanks
Clearmind Medicine files European patent for binge behavior therapy By Investing.com - Investing.com Nigeria
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? - AOL
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - Marketscreener.com
Clearmind Medicine files European patent for binge behavior therapy - Investing.com
Lexitas Elevates Nishat Mehta to CEO, Prepares to Launch AI-Assisted Solutions for the Legal Profession Throughout 2025 - The Manila Times
SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire
SciSparc and Clearmind Secure European Patent for Groundbreaking Binge Behavior Treatment - StockTitan
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - The Manila Times
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - GlobeNewswire Inc.
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder - Marketscreener.com
Clearmind Medicine to move forward with MEAI-based alcohol substitute - Yahoo Finance
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute - EIN News
Clearmind Medicine Partners with Dr Glitter to Develop Crystal-Based Alcohol Alternative - StockTitan
Clearmind Medicine receives IRB approval for Phase I/IIa clinical trial of CMND-100 - MSN
Clearmind Medicine advances in AUD treatment trial By Investing.com - Investing.com South Africa
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Scisparc Ltd. with Clearmind Medicine Inc. Publishes for the Innovative Combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines - Marketscreener.com
Clearmind Medicine Inc. Receives IRB Approval for its FDA-Regulated Clinical Trial - Marketscreener.com
SciSparc Ltd. Announces Finalize an Exclusive Patent License Agreement with Polyrizon Ltd - Marketscreener.com
Clearmind Medicine Inc. Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Marketscreener.com
Scisparc Ltd. and Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - Marketscreener.com
SciSparc Ltd. Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss - Marketscreener.com
BeyondSpring (BYSI) Stock Drops Amidst Biotech Sector Volatility - GuruFocus.com
Why Is Penny Stock Clearmind Gaining Today? - Benzinga
Regulatory Approval Sends Clearmind Medicine (CMND) Soaring Pre-Market - Stocks Telegraph
Clearmind Medicine Shares Double on Trial Approval - MarketWatch
Clearmind Medicine advances in AUD treatment trial - Investing.com
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial - The Manila Times
Clearmind Medicine (NASDAQ:CMND) Shares Up 3.5% – Time to Buy? - Defense World
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format - The Manila Times
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI-Based Alcohol Substitute in ActivCrystal? Format - Marketscreener.com
Clearmind Medicine Partners to Create Revolutionary Crystal-Based Alcohol Alternative - StockTitan
Rail Vision unveils new SaaS platform for rail safety By Investing.com - Investing.com South Africa
Rail Vision unveils new SaaS platform for rail safety - Investing.com
Premium Access Slides: Current Tailwind % Scores and Relative Strength Rank & Trend Reports in a Google Slideshow? - substack.com
Clearmind Medicine (NASDAQ:CMND) Shares Down 12.3% – What’s Next? - Defense World
Bright Minds stock cools amid psychedelic volatility (DRUG:NASDAQ) - Seeking Alpha
Clearmind Medicine Inc [CMND] Revenue clocked in at $0.00 million, down -51.60% YTD: What’s Next? - The DBT News
Clearmind advances trial for alcohol use disorder therapy - Investing.com
Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Clearmind advances trial for alcohol use disorder therapy By Investing.com - Investing.com Australia
Clearmind Medicine Inc (NASDAQ: CMND): Is Its Value Too High Compared To Others? - Stocks Register
Clearmind Medicine Inc Inc. (CMND) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Examining CMND’s book value per share for the latest quarter - US Post News
Clearmind Medicine Inc (CMND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
5.38%
자본화:
|
볼륨(24시간):